Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses
Year: 2017
Type: review
Authors: Gavin Giovannoni, Gary Cutter, Maria Pia Sormani, Shibeshih Belachew, Robert Hyde, Harold Koendgen, Volker Knappertz, Davorka Tomic, David Leppert, Robert Herndon, Claudia A.M. Wheeler-Kingshott, Olga Ciccarelli, David Selwood, Elisabetta Verdun di Cantogno, Ali-Frederic Ben-Amor, Paul Matthews, Daniele Carassiti, David Baker, Klaus Schmierer
Institutions: Queen Mary University of London, Blizard Institute, University of Alabama at Birmingham, University of Genoa, F. Hoffmann-La Roche AG, Biogen (United States), Teva Pharmaceuticals (Israel), Novartis (Switzerland), University of Mississippi Medical Center, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London, UCL Biomedical Research Centre, Merck Serono S.A. (Switzerland), Imperial College London
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Capital award for UK DRI at Imperial College London, Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug, NIHR Senior Investigator Award, Axon and myelin damage assessed using advanced diffusion imaging: from mathematical models to clinical applications, Consortium Building
OpenAlex ID: W2575139667
